Tricuspid Stenosis

• Pressure gradient development: The stenotic valve creates a diastolic pressure gradient between RA and RV that increases with heart rate and cardiac output. Mean gradients >5 mmHg indicate hemodynamically significant stenosis. The RA responds to chronic pressure elevation by developing concentric hypertrophy and chamber dilatation, eventually leading to atrial fibrillation and mechanical dysfunction.

• Systemic venous congestion: Chronically elevated RA pressure (>8 mmHg) is transmitted retrograde through the superior and inferior venae cavae, causing hepatic congestion, splanchnic fluid accumulation, and peripheral edema. This distinguishes TS from mitral stenosis, which typically produces pulmonary congestion. The reduced cardiac output from impaired RV filling may actually limit pulmonary vascular congestion despite elevated RA pressure.

• Right ventricular adaptation: The RV initially compensates through increased contractility to overcome the stenotic obstruction, but prolonged afterload elevation leads to RV dilatation and dysfunction. Right atrial enlargement and increased wall tension paradoxically reduce atrial contractility and increase risk of atrial fibrillation, which further reduces cardiac output through loss of coordinated AV contraction (the "atrial kick" becomes critical in TS).

• Rheumatic heart disease: Accounts for >80% of clinically significant TS, with valve leaflets showing commissural fusion, leaflet thickening, and chordal shortening identical to mitral rheumatic pathology. Rheumatic TS virtually never occurs in isolation but accompanies mitral and/or aortic involvement.

• Carcinoid syndrome: Results from serotonin and other neuroendocrine mediators from midgut neuroendocrine tumors depositing on right-sided valves, causing fibrosis, retraction, and stenosis (often accompanied by tricuspid regurgitation). Classic presentation includes tricuspid involvement with minimal left-sided disease.

• Infective endocarditis: Typically produces regurgitation but can cause stenosis through large vegetations obstructing the valve orifice, particularly in intravenous drug users with right-sided endocarditis.

• Other causes:
• Congenital abnormalities (Ebstein anomaly, hypoplastic tricuspid valve, congenital tricuspid stenosis)
• Pacemaker/ICD lead-related stenosis (increasing incidence with device proliferation)
• Systemic lupus erythematosus and other connective tissue diseases
• Radiation therapy (rare)
• Fenfluramine exposure (historical)
• Myxomatous degeneration (rare)

• Cardinal symptoms:
• Dyspnea on exertion (from reduced cardiac output and elevated pulmonary venous pressure, NOT pulmonary edema)
• Peripheral edema and ascites (often disproportionate to pulmonary congestion)
• Fatigue and exercise intolerance (low cardiac output state)
• Palpitations with atrial fibrillation (common complication)
• Hepatic discomfort from hepatomegaly

• Physical examination findings:
• Prominent RA "a" and "cv" waves: The most characteristic finding, visible as prominent venous pulsations in the JVD with distinctive twin peaks. The "a" wave reflects forceful RA contraction against the stenotic valve; the "cv" (or "s") wave represents RA pressure elevation during ventricular systole without descent (reduced "x" descent).
• Slow "y" descent: Unlike mitral stenosis, the RA pressure does not fall rapidly in early diastole (when RV is not accepting blood), producing a characteristic slow "y" descent on JVD tracing.
• Diastolic rumble: A mid-to-late diastolic murmur at the lower left sternal border (4th-5th intercostal space), best heard with the patient supine or in left lateral decubitus position, increasing with inspiration (increased venous return augments the gradient). Differs from mitral stenosis (apical, left lateral position).
• RV heave: Right ventricular lift along left sternal border if RV hypertrophy develops.
• Hepatomegaly with prominent pulsatile hepatic vein: Pulsatile hepatomegaly with prominent systolic hepatic vein pulsation (from RA pressure transmission).
• Peripheral edema and ascites: Often out of proportion to pulmonary findings.
• Atrial fibrillation: Irregular pulse and loss of "a" waves in JVD as disease progresses.

• Electrocardiography:
• RA enlargement ("P pulmonale" or peaked P waves >2.5 mm in lead II)
• Atrial fibrillation (common in advanced disease)
• RV hypertrophy pattern (right axis deviation, RV strain in advanced cases)
• Nonspecific ST-T changes

• Chest X-ray:
• Dilated RA (prominent right heart border)
• Normal or relatively preserved pulmonary vascularity (unlike mitral stenosis)
• Hepatomegaly and pleural effusions (from venous congestion)

• Transthoracic echocardiography (gold standard):
• Doming of tricuspid leaflets in diastole (thickened, restricted leaflet motion) with commissural fusion
• Reduced tricuspid valve area (TVA <1.5 cm² = significant stenosis; <1.0 cm² = severe)
• Diastolic pressure gradient: Mean TV gradient ≥5 mmHg indicates hemodynamically significant stenosis; >10 mmHg suggests severe stenosis
• RA enlargement with preserved or reduced contractility
• RV cavity dilatation in advanced cases
• Color Doppler to assess for coexisting tricuspid regurgitation (very common)
• Doppler assessment of pulmonary artery pressures

• Transesophageal echocardiography: Better visualization of tricuspid valve anatomy when TTE is inconclusive, particularly useful preoperatively.

• Cardiac catheterization:
• Right heart catheterization directly measures RA and RV pressures with simultaneous recording demonstrating diastolic gradient
• Calculation of tricuspid valve area using Gorlin equation: TVA = CO / (SE × HR × [RA-RV mean diastolic pressure gradient]/1000)
• Assessment of pulmonary hemodynamics and evaluation for pulmonary hypertension
• Left heart catheterization to evaluate concurrent left-sided valve disease and coronary artery disease

• Medical management (temporizing measures):
• Diuretics (loop diuretics preferred): Reduce intravascular volume and diminish systemic venous congestion, alleviating peripheral edema and ascites. Caution: excessive diuresis reduces preload and cardiac output; must maintain adequate filling pressures.
• Sodium restriction (<2 g daily): Reduces volume expansion and symptom burden.
• Rate control for atrial fibrillation: Beta-blockers (metoprolol, carvedilol) or non-dihydropyridine calcium channel blockers (diltiazem, verapamil) to slow ventricular rate and restore AV synchrony; digoxin if systolic dysfunction coexists. Rate control is critical because tachycardia reduces diastolic filling time and worsens hemodynamic compromise.
• Anticoagulation: Warfarin (INR 2-3) if atrial fibrillation develops to reduce thromboembolic risk.
• Vasodilators: Nitrates and ACE inhibitors provide minimal benefit in isolated TS; avoid if hypotension develops.

• Surgical intervention (definitive therapy):
• Tricuspid valve commissurotomy: Preferred for isolated rheumatic TS with pliable leaflets and minimal calcification; can be performed closed or open. Particularly effective in younger patients with isolated stenosis.
• Tricuspid valve replacement: Indicated for severe stenosis, significant calcification, or failed commissurotomy. Bioprosthetic valves preferred in TS given lower thromboembolic risk compared to mitral position (lower flow velocities, less thrombogenic). Mechanical prostheses rarely used given morbidity from chronic anticoagulation.
• Concomitant procedures: TS rarely exists in isolation; mitral valve surgery (almost always required) and/or aortic valve intervention often performed simultaneously.
• Timing: Surgery indicated for symptomatic patients with mean gradient ≥5 mmHg (class I) or asymptomatic patients with significant stenosis undergoing left-sided valve surgery (class IIa).

• Non-pharmacological measures:
• Fluid restriction (1-1.5 L daily in advanced disease)
• Daily weights for volume monitoring
• Activity limitation and exercise restriction
• Avoidance of pregnancy (high-risk condition with hemodynamic decompensation)

• Monitoring:
• Serial echocardiograms every 1-3 years in asymptomatic moderate stenosis; annually if severe
• Functional assessment and symptom evaluation at regular intervals
• Surveillance for development of atrial fibrillation or RV dysfunction

• Atrial fibrillation: Develops in majority of patients with advanced TS secondary to chronic RA enlargement and pressure elevation. Represents major hemodynamic deterioration as loss of atrial contractility reduces already-compromised RV filling. Increases thromboembolic risk and requires anticoagulation.

• Right ventricular dysfunction: Progressive RV dilatation and contractile impairment from chronic pressure overload. Initially preserves ejection fraction but eventually leads to RV systolic dysfunction with reduced cardiac output.

• Severe tricuspid regurgitation: Often coexists with TS; combined lesions markedly worsen hemodynamics and prognosis. Requires surgical management of both valves.

• Hepatic cirrhosis: Prolonged hepatic congestion from chronically elevated RA pressure leads to cardiac cirrhosis with fibrosis and eventual hepatic insufficiency.

• Systemic thromboemboli: Risk elevated with atrial fibrillation, particularly if mitral stenosis coexists (low-flow state promotes thrombosis). Mechanical valve replacement compounds risk.

• Paradoxical embolism: Rare but catastrophic complication if patent foramen ovale or atrial septal defect coexists with right-to-left shunting from elevated RA pressure.

• Prosthetic valve thrombosis or dysfunction: Post-replacement complications requiring redo surgery; higher risk with mechanical prostheses.

Prognostic factors

• Severity of stenosis: Mean gradient >10 mmHg and TVA <1.0 cm² indicate advanced disease with accelerated progression
• Functional class: NYHA class III-IV carries worse prognosis than class I-II
• Concurrent valve disease: Mitral stenosis worsens prognosis substantially; tricuspid regurgitation compounds hemodynamic burden
• Atrial fibrillation: Development of AF indicates advanced remodeling and predicts clinical deterioration
• RV function: RV systolic dysfunction portends poor outcomes
• Pulmonary hypertension: Severe pulmonary hypertension worsens outcomes and surgical risk

• Most important fact: Tricuspid stenosis produces peripheral edema and ascites out of proportion to pulmonary congestion (unlike mitral stenosis), allowing clinical distinction. The key pathophysiology is retrograde venous congestion rather than pulmonary back pressure.

• Classic board buzzword: "Prominent 'a' and 'cv' waves with slow 'y' descent" on jugular venous pulsation is the pathognomonic physical finding that should prompt echocardiographic evaluation.

• Common clinical trap: TS is easily overlooked because it produces subtle findings and coexists with louder mitral stenosis in rheumatic heart disease patients. Listen carefully at the lower left sternal border with patient supine or in left lateral decubitus position, accentuated with inspiration—different position and response to inspiration than mitral stenosis (apical, no inspiratory increase).

• Epidemiologic pearl: TS is increasingly seen as a complication of pacemaker/ICD leads in the modern era; consider in any patient with valvular obstruction and implanted device.

• Pathophysiology mnemonic—"RAVE" (Remember tricuspid stenosis produces):
• Right atrial hypertrophy and enlargement
• Ascites and peripheral edema (venous congestion)
• Venous hypertension (elevated JVD, hepatic congestion)
• Elevated RA pressure gradient

• Diagnostic confidence booster: Mean TV gradient ≥5 mmHg = significant stenosis; <1 cm² TVA indicates hemodynamically significant disease. These values differentiate borderline from definite stenosis.

• Surgical decision point: Combined mitral-tricuspid disease almost always requires surgical intervention on both valves; attempting isolated mitral repair/replacement with neglected significant TS is a major therapeutic error.

• Drug-specific consideration: In TS with AF, rate control is MORE important than in other conditions because ventricular filling is already impaired by stenosis; AF-induced tachycardia compounds the problem catastrophically. Achieve target resting HR <60 bpm.

• Cardiac catheterization finding: The Gorlin equation for tricuspid valve area requires the tricuspid gradient, which is NOT obtained on standard PA/lateral catheterization; must obtain simultaneous RA-RV tracings or use echo-derived values.

• Natural history summary: "Slow to develop, slow to progress, but relentless" — TS often remains asymptomatic for decades then deteriorates progressively; once symptomatic without surgery, prognosis becomes grim.